 Continuous baseline variables will be summarized by typical parameters such as mean, standard deviation and range and compared using two-sample T test on the at-risk and non-risk groups if the normality assumption holds or Wilcoxon rank-sum test if the normality assumption does not hold. Normality of distribution will be determined using the Kolmogorov-Smirnov goodness-of-fit test. Categorical data will be summarized by frequency and percentage and analyzed using the Chi-square or Fishers exact test, as appropriate. Logistic regression will be used to analyze the association of change between after 240 mgm2 and baseline of echocardiography parameters, biomarkers BNP and troponin and pharmacogenomics markers with the primary endpoint, separately. Pharmacogenomics measures will be considered exploratory. Logistic regression will be used to study dosage effect on the primary endpoint. Multi-variable logistic regression will be used to identify independent predictors among echocardiography parameters, biomarkers and pharmacogenomics markers. If the event rate is only 8, we will not be able to perform a multivariate analysis. However, this event rate is highly variable, and a substantially higher event rate from 16-20 has been noted in more recent studies. If the event rate is only 8, we will not be able to perform a multivariate analysis, but if it is 16-20, we should be able to fit some multivariable models without overfitting. Hence, we will only consider performing a multivariate analysis if the event rate is at least 16-20. All analysis will be performed in SAS and SPSS. Strain cut-off levels defining risk vs. non-risk will be a 20 relative decrease in global longitudinal strain. For the secondary objectives, the cutoff value for troponin will be 0.08 ngmL at any time. For BNP the cutoff value will be 200 pgmL at any time. 